Cargando…

Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout

AIMS : With the high prevalence of gout and associated cardiovascular (CV) diseases, information on the comparative CV safety of individual urate-lowering drugs becomes increasingly important. However, few studies examined the CV risk of uricosuric agents. We compared CV risk among patients with gou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Eun Ha, Park, Eun Hye, Shin, Anna, Song, Jung Soo, Kim, Seoyoung C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633759/ https://www.ncbi.nlm.nih.gov/pubmed/34508567 http://dx.doi.org/10.1093/eurheartj/ehab619

Ejemplares similares

Cardiovascular risk associated with allopurinol or benzbromarone treatment in patients with gout
por: Eun, Yeonghee, et al.
Publicado: (2022)

Allopurinol, Benzbromarone, or a Combination in Treating Patients with Gout: Analysis of a Series of Outpatients
por: Azevedo, Valderilio Feijó, et al.
Publicado: (2014)

Sex differences in response to allopurinol and benzbromarone in gout: a retrospective cohort study
por: Veenstra, Frouwke, et al.
Publicado: (2021)

Comparison of Benzbromarone and Allopurinol on Primary Prevention of the First Gout Flare in Asymptomatic Hyperuricemia
por: Lai, Shih-Wei, et al.
Publicado: (2022)

Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
por: Pawar, Ajinkya, et al.
Publicado: (2021)

Reduced Incidence of Stroke in Patients with Gout Using Benzbromarone
por: Niu, Sheng-Wen, et al.
Publicado: (2022)

The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study
por: Xue, Xiaomei, et al.
Publicado: (2020)

A Head-To-Head Comparison of Benzbromarone and Allopurinol on the Risk of Type 2 Diabetes Mellitus in People With Asymptomatic Hyperuricemia
por: Lai, Shih-Wei, et al.
Publicado: (2021)

Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes
por: Singh, Jasvinder A., et al.
Publicado: (2017)

African American patients with gout: efficacy and safety of febuxostat vs allopurinol
por: Wells, Alvin F, et al.
Publicado: (2012)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
por: Guan, Xudong, et al.
Publicado: (2022)

The risk of ischemic cerebrovascular disease associated with benzbromarone use in gout people: A retrospective cohort study in Taiwan
por: Lai, Shih-Wei, et al.
Publicado: (2023)

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol
por: Perez-Ruiz, Fernando, et al.
Publicado: (2016)

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

Hyperuricaemia, gout and allopurinol in the CKD Queensland registry
por: Jeyaruban, A., et al.
Publicado: (2021)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Gao, Linggen, et al.
Publicado: (2021)

Effect of Clinical Typing on Serum Urate Targets of Benzbromarone in Chinese Gout Patients: A Prospective Cohort Study
por: Xue, Xiaomei, et al.
Publicado: (2022)

`Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea
por: Jeong, Hoon, et al.
Publicado: (2022)

Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol
por: Dalbeth, Nicola, et al.
Publicado: (2018)

Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients
por: Cheng, Ching-Lan, et al.
Publicado: (2022)

Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis
por: Zhang, Shengzhao, et al.
Publicado: (2021)

Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Deng, Jian‐Hao, et al.
Publicado: (2022)

Gout, flares, and allopurinol use: a population-based study
por: Proudman, Charlotte, et al.
Publicado: (2019)

Current state and prospects of gout treatment in Korea
por: Park, Eun Hye, et al.
Publicado: (2022)

Reply to comment on “Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis”
por: Gao, Linggen, et al.
Publicado: (2022)

Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout
por: Ali, Zakir, et al.
Publicado: (2022)

Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study
por: Hosoya, Tatsuo, et al.
Publicado: (2020)

Benzbromarone, Quercetin, and Folic Acid Inhibit Amylin Aggregation
por: López, Laura C., et al.
Publicado: (2016)

The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout
por: Baumgartner, Scott, et al.
Publicado: (2018)

Allopurinol Therapy in Gout Patients Does Not Associate with Beneficial Cardiovascular Outcomes: A Population-Based Matched-Cohort Study
por: Kok, Victor C., et al.
Publicado: (2014)

A Case of Allopurinol-Induced Fixed Drug Eruption Confirmed With a Lymphocyte Transformation Test
por: Kim, Min-Hye, et al.
Publicado: (2012)

Superiority of Low‐Dose Benzbromarone to Low‐Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion
por: Yan, Fei, et al.
Publicado: (2022)

Risk of Non-Vertebral Fracture in Gout Compared to Rheumatoid Arthritis
por: Cho, Soo-Kyung, et al.
Publicado: (2021)

Cost-effectiveness of allopurinol versus febuxostat in the treatment of gout patients: A systematic review
por: Rezapour, Aziz, et al.
Publicado: (2020)

Retraction Note: Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout
por: Ali, Zakir, et al.
Publicado: (2023)

The EYA Tyrosine Phosphatase Activity Is Pro-Angiogenic and Is Inhibited by Benzbromarone
por: Tadjuidje, Emmanuel, et al.
Publicado: (2012)

Benzbromarone Stabilizes ΔF508 CFTR at the Cell Surface
por: Loo, Tip W., et al.
Publicado: (2011)

A neutrophil signature is strongly associated with increased cardiovascular risk in gout
por: Vedder, Daisy, et al.
Publicado: (2020)

Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial
por: Dewi, Christiyanti, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q6o3vqvqace5vk2nkft0n3tgl5